– Appointment supports revenue quality and profitability momentum as the Company activates its transformed operating base
– Company announces further operational progress in its Comprehensive Transformation Plan
– Company publishes Q4 2025 financial results with revenue broadly in line with previously issued trading update & year-on-year gross margin percentage improvements
Trinity Biotech plc, a commercial‑stage diagnostics and health technology company, announced the appointment of Jerry Lydon as Head of North America Commercial Operations.
Mr. Lydon’s appointment represents a deliberate next step as the Company’s core diagnostics business transitions from the execution phase of its Comprehensive Transformation Plan toward a sustained focus on building revenue momentum and, importantly, driving profitability from a more efficient and disciplined operating base.
The appointment also aligns with recent upgrades to the Company’s Premier HbA1c 9210™ platform, the Company’s laboratory blood glucose monitoring solution. The enhanced Premier Hb9210™ platform recently became the only HbA1c system worldwide to receive the prestigious International Federation of Clinical Chemistry “Gold” classification for 2026, a designation recognising the highest levels of clinical accuracy, precision and traceability.
Read More: SalesTechStar Interview with Sahil Rekhi, Chief Revenue Officer at Graia
Over the past two years, Trinity has implemented a wide‑ranging transformation program designed to simplify its operating footprint, improve cost control, rationalise manufacturing, and prioritise profitability. With many of these foundational actions substantially completed, management is now focused on extracting greater operating leverage and financial returns from that improved structure, including across the North America business.
Jerry Lydon brings extensive commercial leadership experience in diagnostics and healthcare, with a strong track record of improving sales execution, managing distributor and direct sales channels. In his role, Mr. Lydon will oversee Trinity’s North America commercial organisation, with responsibility for commercial execution across the core diagnostics portfolio.
As part of this role, Mr. Lydon will lead commercial operations for the Company’s New York State Department of Health–approved reference laboratory, including supporting the commercialisation planning for a pipeline of new products in development, such as:
- EpiCapture, a proprietary epigenetic assay for prostate cancer monitoring, and
- PrePsia, a proprietary early-pregnancy blood test to assess risk of developing preeclampsia, a serious pregnancy complication.
Commenting on the appointment, John Gillard, President & Chief Executive Officer of Trinity Biotech, said:
“Jerry’s appointment reflects our focus on strengthening execution and improving the quality and profitability of revenue in North America. Following an intensive transformation program, our priority in our core diagnostics business is to generate sustainable financial improvement from the operating base we have put in place. Jerry’s experience will be important both in advancing key products such as the upgraded Premier HbA1c 9210 and in supporting the commercial readiness of our NYSDOH‑approved reference lab and its development pipeline. It is a timely appointment in terms of supporting and strengthening the core business while we continue to drive our broader innovation agenda.”
Mr. Lydon added:
“The Company has made important changes to its operating and cost structure, while selectively investing in product upgrades and introductions. My focus is on disciplined commercial execution—supporting customers, strengthening channels, and ensuring that revenue growth is aligned with profitability and operational performance.”
Continued Progress Across the Comprehensive Transformation Plan
The Company also highlighted continued progress across key elements of its transformation plan, with several initiatives now moving from implementation to financial contribution:
- TrinScreen™ HIV manufacturing under the outsourced operating model has been successfully scaled, recently reaching targeted production levels by early Q2 2026.
- Uni‑Gold™ HIV manufacturing under the outsourced structure commenced during Q2 2026 and is currently being scaled following regulatory approval received in in early 2026.
Both initiatives are expected to support revenue and profitability from Q2 2026 onwards, reflecting the benefits of a more variable cost structure, improved gross margins, and reduced operational complexity.
Read More: SalesTech for Sales Email Engagement – What Works and What Doesn’t
